Procalcitonin in early onset ventilator-associated pneumonia

The Journal of Hospital Infection
U Zielińska-BorkowskaB Czarnocka

Abstract

Ventilator-associated pneumonia (VAP) is a significant problem in intensive care and there exists great demand for a suitable biomarker. Procalcitonin (PCT) has been proposed as a candidate marker. To assess the clinical usefulness of monitoring PCT concentrations in non-surgical patients with early onset VAP. Thirty-four patients were enrolled with early onset VAP defined as VAP diagnosed between 48 h and 6 days of the onset of mechanical ventilation. Serum PCT was measured on days 1, 2, 3, 5, 6 and 7. The mortality rate was 21%. Non-survivors had significantly elevated PCT levels on days 3 and 7. For non-survival, the areas under the receiver operator curve (AUC) for PCT were 0.762 [95% confidence interval (CI): 0.6-0.923] on day 3 and 0.754 (95% CI: 0.586-0.922) on day 7. Among septic patients, PCT was significantly higher on days 1, 2, 3, 5, and 7, with the highest AUC on day 1 (0.783; 95% CI: 0.626-0.94): a cut-off of 1 ng/mL on day 1 had a positive predictive value of 0.813 for the development of septic shock. No association was found between PCT concentration and the adequacy of antibiotic therapy or the aetiology of VAP. In logistic regression analysis, PCT was not significantly correlated with poor outcome. Although PC...Continue Reading

References

Oct 1, 1985·Critical Care Medicine·W A KnausJ E Zimmerman
Feb 26, 1997·JAMA : the Journal of the American Medical Association·F BregeonF Gouin
Apr 13, 1999·Critical Care Medicine·H UgarteJ L Vincent
May 8, 2003·Intensive Care Medicine·Joachim E FischerRoman Jaeschke
Sep 28, 2004·American Journal of Respiratory and Critical Care Medicine·Charles-Edouard LuytJean Chastre
Feb 18, 2005·Acta Anaesthesiologica Scandinavica·R SarbinowskiA Bengtsson
Oct 11, 2005·Critical Care Medicine·Nasia SafdarSanjay Saint
Aug 11, 2006·Chest·Ilana Porzecanski, David L Bowton
Feb 24, 2007·The Lancet Infectious Diseases·Benjamin M P TangAnthony S McLean
Jun 3, 2008·Burns : Journal of the International Society for Burn Injuries·Mitra BaratiHamid Karimi
Dec 7, 2010·The Journal of Hospital Infection·E J Giamarellos-BourboulisUNKNOWN Hellenic Sepsis Study Group

❮ Previous
Next ❯

Citations

Dec 15, 2015·Respirology : Official Journal of the Asian Pacific Society of Respirology·Dan LiuLi-Xin Xie
Dec 9, 2016·Clinical Chemistry and Laboratory Medicine : CCLM·Urszula Zielińska-BorkowskaTomasz Skirecki
Aug 7, 2014·Clinical and Translational Medicine·Ornella Piazza, Xiangdong Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Critical Care : the Official Journal of the Critical Care Forum
Renato SeligmanPaulo J Z Teixeira
Burns : Journal of the International Society for Burn Injuries
L BarguesH Carsin
Current Opinion in Pulmonary Medicine
Graciela J Soto
© 2021 Meta ULC. All rights reserved